Combinatorial chemoprevention of intestinal neoplasia |
| |
Authors: | Torrance C J Jackson P E Montgomery E Kinzler K W Vogelstein B Wissner A Nunes M Frost P Discafani C M |
| |
Institution: | The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA. |
| |
Abstract: | A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed approximately 20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|